New cancer clinical trial: M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

Published on: August 15, 2018 at 12:00PM
Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: M7824;   Drug: Pembrolizumab
Sponsors:   EMD Serono Research & Development Institute, Inc.;   Merck KGaA
Not yet recruiting
https://ift.tt/2vOZMCz